Articles tagged with Positron Emission Tomography
Researchers at Massachusetts General Hospital developed PET/CT imaging to assess carotid plaque inflammation, identifying patients at high risk for heart attacks. This breakthrough may lead to more targeted interventions and improved patient outcomes.
Researchers found a link between increased serotonin receptors and body weight in overweight individuals. The discovery suggests that serotonin receptor manipulation could be a potential target for treating obesity.
Researchers have found that an ADHD medication 'harmonizes' with the body's dopamine system, improving attention and focus in individuals. The study, presented at a medical conference, provides direct evidence of the drug's beneficial effect, which was previously speculative.
Gambhir, a renowned Stanford University scientist, is recognized for his extensive work in molecular imaging and basic science of using radioactive tracers. He has developed numerous methods for imaging gene/cell therapy and protein-protein interactions in living subjects.
A new time-of-flight PET scanner with LYSO detector crystals improves diagnostic accuracy and reduces variability in patient images. This technology enables more accurate detection of small lesions and better lesion characterization, leading to improved cancer diagnosis and treatment.
Walter Wolf, distinguished professor of pharmaceutical sciences at USC, received the award for his groundbreaking work in pharmacokinetic imaging and radiopharmaceuticals. His research focuses on noninvasive studies of drug biodistribution and targeting using nuclear medicine imaging and magnetic resonance spectroscopy.
A new study finds that using PET and CT scans together during radiation therapy planning reduces errors due to patient motion, allowing for more accurate targeting of cancer cells. This approach may lead to more effective treatment with lower side effects.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has released a landmark procedure guideline for tumor imaging with 18F-FDG PET/CT. The document provides recommendations for patient preparation, image acquisition, interpretation criteria, and quality control to ensure high-quality imaging results.
A Hopkins-led clinical study found that men's brains show a significantly higher dopamine release in response to amphetamines compared to women. This discovery may lead to more effective treatments for amphetamine abuse and brain diseases.
Researchers used PET scans to evaluate response to chemoradiation in esophageal cancer patients. The study found that PET was 88% accurate at identifying patients without disease, potentially changing clinical practice and allowing some patients to avoid surgery.
A study published in Annals of Surgery found that PET imaging was 88% accurate in identifying patients without disease after chemoradiation. This technology has the potential to change clinical practice by helping some patients avoid surgery.
A study in the Journal of Nuclear Medicine Technology found that physical activity, even minor exercises like turning a page or shoveling snow, can impact PET scan results and lead to false positives. To minimize this effect, patients should avoid excessive muscle activity 48 hours before scanning and inform their technologist.
Researchers used PET and MR imaging to show white matter volume loss precedes clinical symptoms of Huntington's disease. The study suggests a new approach to preventing the disease at an early stage by monitoring brain tissue volumes and basal ganglia dysfunction.
A study published in Annals of Neurology found that brain scans can predict cognitive decline in normal older people, with lower glucose metabolism detected in the parietal and temporal lobes. The scans also predicted declines on memory tests, such as the DelRec test, suggesting a potential link to Alzheimer's disease.
A recent study published in Chemical Senses found that the sense of smell is dependent on body position. Researchers at McGill University exposed participants to different concentrations of rose odor while sitting or lying down and discovered a significant decrease in sensitivity to smell when in a supine position.
PET imaging has shown to be a valuable tool in improving cancer care management by accurately assessing treatment outcomes and monitoring tumor response. Studies have demonstrated that PET can detect residual scar tissue rather than viable tumor, leading to changes in how PET is used in cancer care.
Researchers at UCLA have developed a new method to track neuronal cell death in the hippocampus, a key memory center, which may lead to early detection and treatment of Alzheimer's disease. The study found that 49% of Alzheimer's patients and 24% of mild cognitive impairment patients showed significant density decreases.
A new programmable chip has been developed to accelerate the production of molecular imaging molecules for PET, with a 93% accuracy in detecting Alzheimer's disease. The technology enables mass production of diverse imaging molecules and applications for PET in biology and pharmaceutical research.
David Eidelberg receives the prestigious Fred Springer Award for his work on mapping brain pathways and developing new diagnostic techniques. The award recognizes his pioneering efforts in viewing the brain at work, early diagnosis, and predicting treatment responses.
UCLA researchers have developed a new method to monitor the immune system's response to cancer using PET scans. This breakthrough could lead to faster and more effective ways to test immunotherapies and track human responses to cancer treatments.
Researchers developed a new PET technique to visualize the immune system's response to tumors and diseases. This non-invasive method enables clinicians to see key cells and their interactions, improving diagnosis and treatment precision.
PET imaging with FDG is a powerful tool in determining the extent of spread of reproductive system cancers, particularly when other conventional tests are ambiguous. Studies have shown its high sensitivity in detecting nodal disease in cervical cancer and its superior detection abilities compared to CT or MRI in recurrent ovarian cancer.
By combining functional MRI and PET scanning, researchers can gain a more comprehensive view of the brain's functions and explore different aspects of its activity. This new technique allows physicians to better diagnose and treat patients with brain disorders such as stroke, seizure disorders, and neurodegenerative diseases.
A study published in Journal of Nuclear Medicine found that PET imaging with FDG has significantly higher accuracy than genetic screening for predicting Alzheimer's disease in mild cognitive impairment (MCI) patients. Most MCI patients who showed abnormalities in their original PET scan developed dementia within 16 months.
The SNM/GE Healthcare Visiting Physician/Scientist Program Grant will provide educational enrichment in China and India through one- to two-week visits. Clinical centers, hospitals, academic institutions can apply for funding to support nuclear medicine/molecular imaging training and consulting.
Researchers have found that a marker for serotonin systems can identify epilepsy-generating brain areas, even in patients with normal MRI scans. This breakthrough has the potential to reduce the need for invasive EEG studies and improve surgical outcomes for patients with uncontrolled seizures.
A study found that fetal alcohol exposure can alter the dopamine system in monkeys, affecting cognition and behavior. The timing of exposure during gestation varies the impact, with early exposure blunting the system and later exposure leading to supersensitive receptors.
Researchers found reduced MAO A levels in smokers' lungs, which may contribute to physiological effects of smoking like changes in blood pressure and pulmonary function. Smokers also retained tracer chemicals longer and had lower delivery into arterial blood supply.
Researchers used PET scanning to track monoamine oxidase (MAO A) levels in smokers and nonsmokers, finding that MAO A was 50% lower in smokers' lungs. Smokers also held onto a tracer chemical longer and had reduced delivery of tracer into arterial blood supply.
A team of researchers developed a tracer molecule to highlight beta-amyloid in PET brain scans, aiming to diagnose Alzheimer's disease earlier. PET biomarkers could also evaluate the effects of drugs on the brain, potentially improving treatment outcomes for neurodegenerative conditions.
A new dye, NIAD-4, has been developed to allow direct imaging of Alzheimer's plaques through a patient's skull without invasive procedures. The compound binds to amyloid brain plaques and fluoresces when exposed to near-infrared radiation, providing clear visual images.
Researchers accurately predicted fMRI signals in patients while watching a movie, validating its use in human neuroscience research. The findings also highlight the importance of further study to understand the correlation between fMRI and single neuronal activity.
A new study suggests that PET imaging can identify which breast cancer patients are likely to respond to chemotherapy, allowing for more effective treatment and improved patient outcomes. This breakthrough could lead to the development of personalized treatment plans, giving patients and doctors more options.
A new study from UNC Health Care found that whole-body PET/CT scanners are highly accurate in detecting the spread and recurrence of head and neck cancer. The scans can pick up cancer where none was thought to exist, allowing for more precise biopsies and treatment planning.
Researchers discovered that bound NADH molecules rotate more slowly, affecting fluorescence levels in diagnostic tests. This finding resolves long-standing inconsistencies and enables better interpretation of quantitative data from diagnostic techniques.
Researchers at Stanford University have developed a novel 3D rendering technique for PET/CT images, allowing for simultaneous viewing of multiple modalities. This new paradigm has the potential to revolutionize diagnostic and treatment procedures for various diseases.
A recent UCLA study has found a significant association between obesity and impaired coronary circulatory function, highlighting the importance of early detection and monitoring. Quantitative PET imaging may help identify at-risk individuals, enabling targeted interventions to prevent cardiovascular events.
Acute respiratory distress syndrome (ARDS) can be predicted using PET scans in trauma patients, allowing for early treatment with aggressive immune modulation therapy. This method has the potential to reduce mortality rates and improve patient outcomes.
The Cleveland Clinic Health System has implemented a mobile PET/CT unit, providing on-site cancer diagnosis to patients in need. The cooperative efforts of all involved hospitals have made the service a successful operation.
Caffeine can increase heart activity, making it harder to see cancerous lesions on scans. Patients who consumed coffee before scans had higher myocardial uptake than those with low or no caffeine intake.
A study using PET scans found that cognitive behavioral therapy alters brain chemistry in patients with bulimia nervosa, particularly in regions related to feeding and reward. The results suggest a relationship between opioid receptors and bulimic behavior, potentially informing more effective treatment strategies.
The Gamma Medica imaging system enables researchers to use PET only, CT only, or a combination of modalities, allowing for flexibility and efficiency in research objectives. This tri-modality system is expected to speed up the development of life-saving drugs by enabling faster and more efficient work.
A recent study found that caffeine intake can significantly affect myocardial uptake on PET/CT scans, making it harder to detect lesions near the heart. Researchers recommend avoiding caffeine and exercise before imaging to ensure a clear view of the body.
A German-developed expert system enhances the diagnostic accuracy of Alzheimer's disease using FDG PET scans. The system, which was tested in 150 cases, helps inexperienced physicians diagnose Alzheimer's and differentiate it from other dementia disorders.
Researchers from Munich discovered that sequential FDG-PET can identify responding tumors after just one cycle of chemotherapy, allowing for earlier assessment of treatment efficacy. This could lead to more accurate individualized treatment and improved patient outcomes.
Researchers have successfully applied a novel PET/CT technique to characterize the effects of a gene therapy intervention in animal models, demonstrating its potential for improving cardiac health. The study showed that successful transfer of a VEGF gene resulted in increased tissue perfusion without impairing cardiac function.
A new computer program, HipMask, uses brain scans to predict future Alzheimer's disease, offering a possible tool for early screening. The technique measures metabolic activity in the hippocampus, which diminishes in size as Alzheimer's progresses.
Larson, a leading expert in targeted radiotherapy and molecular imaging, has made significant contributions to the advancement of positron emission tomography (PET) as a clinical tool for oncology. His research has led to novel findings in cancer understanding and treatment.
David James Brooks, a pioneer in applying PET to movement disorders, received the Kuhl-Lassen Award for his groundbreaking research on Parkinson's and related disorders. His work has improved understanding of disease progression, diagnosis, and therapeutics.
A new approach to PET imaging scans may help diagnose more cancerous lesions, with Saint Louis University researchers finding that up to 8% of cancerous legions occur outside the current imaging field. The true whole-body scan protocol has been successfully tested and could become the standard for all PET centers.
Researchers used PET/CT scans to evaluate nearly 2,000 cancer patients and detected unexpected additional malignancies. These newly identified lesions are often of early stage and have a better likelihood of being cured if treated promptly and aggressively.
Small animal imaging allows for repeated, non-invasive studies on the same living subject, providing crucial information on disease progression and treatment outcomes. This technology enables researchers to gain insights into human biology and disease, leading to improved diagnosis and development of innovative drugs.
Researchers have developed a marker to measure new blood vessel growth in tumors using positron emission tomography (PET) scanning and a fluorine-labeled glycopeptide. The marker, αvβ3 integrin, can identify tumors that express this marker, assess new vessel formation, and guide anti-angiogenic therapies.
A new study suggests that PET scanning is more accurate than SPECT in detecting heart disease, leading to a significant decrease in the use of invasive procedures like angiograms and bypass surgery. This could result in cost savings of up to 25% for patients managed with PET scanning.
Researchers used PET/CT to diagnose foot infections in diabetics by detecting glucose uptake with labeled radiotracer 18F-FDG. This approach facilitated better localization of infection and structural changes in bone and soft tissues, showing promise for more accurate diagnoses.
A study of surgically implanted electrodes in patients with refractory depression found significant clinical response in four out of six participants, with sustained improvement through six months. The technique involves high-frequency electrical stimulation to modulate brain activity in the subgenual cingulate region.
The study used combined PET and MRI to track cocaine pharmacokinetics in pregnant nonhuman primates. The results showed that cocaine accumulated at the highest levels in the liver, and to a lesser extent in the brain, suggesting a unique anatomy of fetal circulation.
Researchers have developed a new fluorine-18 labeled imaging agent, nifrolidine, which binds to a receptor involved in cognition and learning. This receptor is also linked to nicotine addiction and lung cancer, making it a potential target for early Alzheimer's disease diagnosis and treatment.
Researchers have identified a potential therapeutic application for the new drug Nifrolidine in treating nicotine addiction and Alzheimer's disease. The study found that Nifrolidine binds to specific brain receptors implicated in these conditions, offering hope for early diagnosis and treatment.
The study found that PET/CT imaging was effective in detecting new malignancy and precisely localizing disease extent in patients with suspected occult recurrent cancer. The imaging modality provided valuable information for treatment planning, potentially avoiding further invasive procedures.